Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01806779 · ClinicalTrials.gov registry record · Phase 2
Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 376
- Enrollment target
NCT01806779 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 376 participants.
The verdict
NCT01806779, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 376 participants
- Enrollment target
Study Summary
Previous results from the investigators' Center have shown that combination treatment with Chantix and Zyban is more successful in helping men quit smoking. The investigators hope to replicate these findings with this study.
Interventions
- DRUG Zyban
- DRUG Chantix
- DRUG Nicotine patches
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01806779
The ClinicalTrials.gov registry entry for NCT01806779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zyban is the first listed.
NCT01806779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01806779 about?
NCT01806779 is a clinical study titled "Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers". Previous results from the investigators' Center have shown that combination treatment with Chantix and Zyban is more successful in helping men quit smoking. The investigators hope to replicate these findings with this study.
What is the current status of trial NCT01806779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 376 participants. The study started on 2013-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01806779?
The interventions under investigation include: Zyban (DRUG), Chantix (DRUG), Nicotine patches (DRUG).
Who is sponsoring clinical trial NCT01806779?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.